226 related articles for article (PubMed ID: 11505288)
1. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
2. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
3. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
4. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
5. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
6. [Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose].
Hellwig D; Gröschel A; Rentz K; Sybrecht GW; Kirsch CM; Ukena D
Pneumologie; 2001 Aug; 55(8):363-6. PubMed ID: 11505287
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients.
Li J; Xu W; Kong F; Sun X; Zuo X
Surg Oncol; 2013 Sep; 22(3):151-5. PubMed ID: 23664848
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
10. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer.
Baum RP; Hellwig D; Mezzetti M
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):119-42. PubMed ID: 15243408
[TBL] [Abstract][Full Text] [Related]
11. PET in lung cancer staging.
Coleman RE
Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
[TBL] [Abstract][Full Text] [Related]
12. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review.
Hellwig D; Baum RP; Kirsch C
Nuklearmedizin; 2009; 48(2):59-69, quiz N8-9. PubMed ID: 19333516
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
[TBL] [Abstract][Full Text] [Related]
16. [Positron emission tomography (PET) with [18F]-FDG in bronchopulmonary cancer and its impact on medical decision at the time of diagnosis, staging, or recurrence evaluation].
Grahek D; Montravers F; Mayaud C; Regnard JF; Kerrou K; Younsi N; Talbot JN
Rev Pneumol Clin; 2001 Dec; 57(6):393-403. PubMed ID: 11924148
[TBL] [Abstract][Full Text] [Related]
17. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
19. Utility of 18F-FDG PET in evaluating cancers of lung.
Acker MR; Burrell SC
J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
[TBL] [Abstract][Full Text] [Related]
20. The importance of 18F-FDG PET/CT, CT and X-rays in detecting primary stage III A lung cancer and the incidence of extra thoracic metastases.
Sharma R; Tripathi M; D'Souza M; Jaimini A; Saw SK; Singh D; Mishra A; Mondal A
Hell J Nucl Med; 2009; 12(1):22-5. PubMed ID: 19330177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]